Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 1,001–1,100 of 4,108
Yang, R., Deng, H., Hou, J., Li, W., Zhang, C., Yu, M., Tang, Y., Li, Q., Li, F., Song, B., et al. (2020) · Journal of Orthopaedic Research® · doi:10.1002/jor.24571 · Cited by 31
“sCT is also approved to treat postmenopausal osteoporosis in women who are greater than 5 years postmenopause when alternative treatments are unsuitable.(17) Since frozen shoulder commonly affects people in their 50s, some of the patients may present with osteoporosis.”
BackgroundChisati, E. M., Constantinou, D., & Lampiao, F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227893 · Cited by 28
Acupuncture and moxibustion for primary osteoporosis: An overview of systematic review
Xu, G., Xiao, Q., Zhou, J., Wang, X., Zheng, Q., Cheng, Y., Sun, M., Li, J., & Liang, F. (2020) · Medicine · doi:10.1097/md.0000000000019334 · Cited by 29
“After the age of 50, Osteoporosis becomes much more common, particularly for postmenopausal women.([2,3]) Osteoporosis is a major health problem because of the fractures that lead to impair the quality of life as well as increases economic burden worldwide.”
BackgroundBögl, H. P., Zdolsek, G., Michaëlsson, K., Höijer, J., & Schilcher, J. (2020) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.20.00160 · Cited by 26
Denosumab for cancer-related bone loss
Dell’Aquila, E., Armento, G., Iuliani, M., Simonetti, S., D’Onofrio, L., Zeppola, T., Madaudo, C., Russano, M., Citarella, F., Ribelli, G., et al. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1814731 · Cited by 27
Khired, Z. A., El–Akabawy, G., Alsebail, R. A., Alotaibi, A. E., Alblowi, N. S., Albalawi, H. K., & Alrussayes, S. S. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-020-00865-7 · Cited by 26
Ahn, S., & Oh, J. (2021) · Applied Nursing Research · doi:10.1016/j.apnr.2021.151430 · Cited by 29
Takahashi, K., Nishikawa, K. K. N., Furukawa, K., Tanishima, Y., Ishikawa, Y., Kurogochi, T., Yuda, M., Tanaka, Y., Matsumoto, A., Mitsumori, N. N. M., et al. (2021) · World Journal of Surgery · doi:10.1007/s00268-021-06199-w · Cited by 24
Park, H. W., Jung, H., Back, K., Choi, H. J., Ryu, K. S., Cha, H. S., Lee, E. K., Hong, A. R., & Hwangbo, Y. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00880-x · Cited by 28
Albrecht, B. M., Stalling, I., Foettinger, L., Recke, C., & Bammann, K. (2022) · Nutrients · doi:10.3390/nu14122463 · Cited by 30
“Osteoporosis—the most common bone disease [1]—is characterized by low bone mass and a microarchitectural deterioration of bone tissue [2], which lead to a higher risk for fractures [3].”
BackgroundChavda, S., Chavda, B., & Dube, R. (2022) · Cureus · doi:10.7759/cureus.26518 · Cited by 32
“Lifestyle factors, hereditary diseases, hypogonadal states, endocrine disorders, gastrointestinal disorders, hematologic disorders, rheumatologic and autoimmune diseases, neurological and musculoskeletal risk factors, medicines, and other conditions and diseases fall under this category and are shown in Table 2 [2].”
BackgroundRisk factors of refracture after a fragility fracture in elderly
Sriruanthong, K., Philawuth, N., Saloa, S., Daraphongsataporn, N., & Sucharitpongpan, W. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01143-4 · Cited by 31
“However, the vertebral, wrist, and proximal humerus fracture patients should also be included in the fracture liaison service (FLS) to decrease refractures and mortalities [15, 26, 27].”
BackgroundResultCT and MR for bone mineral density and trabecular bone score assessment in osteoporosis evaluation
Lee, H., Park, S., Kwack, K., & Yun, J. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-43850-z · Cited by 27
Fragility Fractures Requiring Special Consideration
Humphrey, C. A., & Maceroli, M. A. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.01.012 · Cited by 49
Unni, S. K., Yao, Y., Milne, N., Gunning, K. M., Curtis, J. R., & Lafleur, J. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2899-7 · Cited by 27
Exercise Preferences Among Men With Prostate Cancer Receiving Androgen-Deprivation Therapy
Harrington, J. M., Schwenke, D. C., & Epstein, D. R. (2013) · Oncology nursing forum · doi:10.1188/13.onf.e358-e367 · Cited by 35
The Malaysian Clinical Guidance on the Management of Postmenopausal Osteoporosis, 2012: A Summary
Yeap, S. S., Hew, F. L., Lee, J. K., Goh, E. M. L., Chee, W. S. S., Mumtaz, M., Damodaran, P., Lim, H. H., & Chan, S. P. (2013) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12037 · Cited by 28
Lee, R., Lyles, K. W., Pearson, M., Barnard, K., & Colon-Emeric, C. S. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9849-4 · Cited by 25
Ruff, J. M., Wang, T. L., Quatman‐Yates, C. C., Phieffer, L. S., & Quatman, C. E. (2014) · Injury · doi:10.1016/j.injury.2014.08.047 · Cited by 30
The Demographic Changes of Menopausal and Geripausal Women in Korea
Kim, M. Y., Im, S.-W., & Park, H. M. (2015) · Journal of Bone Metabolism · doi:10.11005/jbm.2015.22.1.23 · Cited by 25
The Adequacy of Diagnosis and Treatment for Osteoporosis in Patients with Proximal Humeral Fractures
Kim, T. I., Choi, J. H., Kim, S. H., & Oh, J. H. (2016) · Clinics in Orthopedic Surgery · doi:10.4055/cios.2016.8.3.274 · Cited by 25
Low bone mineral density and associated risk factors in HIV-infected patients
Chițu, C. E., Barbu, E.-C., Lazăr, M., Ion, D. A., & Bădărău, I. A. (2016) · GERMS · doi:10.11599/germs.2016.1089 · Cited by 24
Lewis, R. C., Johns, L. E., & Meeker, J. D. (2016) · Chemosphere · doi:10.1016/j.chemosphere.2016.08.142 · Cited by 26
A Survey of Women's Awareness of and Reasons for Lack of Postfracture Osteoporotic Care
Boudreau, D. M., Yu, O., Balasubramanian, A., Wirtz, H. S., Grauer, A., Crittenden, D. B., & Scholes, D. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14921 · Cited by 31
Li, X., Ye, J.-X., Xu, M.-H., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4017-0 · Cited by 25
Luc, M., Corriveau, H., Boire, G., Filiatrault, J., Beaulieu, M., & Gaboury, I. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15050944 · Cited by 27
A study of the value of trabecular bone score in fracture risk assessment of postmenopausal women
Mirzaei, A., Jahed, S. A., Nojomi, M., et al. (2018) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2018.04.011 · Cited by 25
Guo, R., Wu, L., & Fu, Q. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0452-y · Cited by 29
Tamai, K., Terai, H., Suzuki, A., Nakamura, H., Watanabe, K., Katsumi, K., Ohashi, M., Shibuya, Y., Izumi, T., Hirano, T., et al. (2018) · Spine Surgery and Related Research · doi:10.22603/ssrr.2018-0068 · Cited by 26
Therkildsen, J., Winther, S., Nissen, L., Jørgensen, H., Thygesen, J., Ivarsen, P., Frost, L., Langdahl, B., Hauge, E., & Bøttcher, M. (2020) · Journal of clinical densitometry · doi:10.1016/j.jocd.2018.12.002 · Cited by 21
Su, F., Liu, D.-H., Chen, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130716 · Cited by 25
Sylvestre, V. T., & Dunton, C. J. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0007-9 · Cited by 25
Osteoporosis and depression in perimenopausal women: From clinical association to genetic causality
Guo, X., She, Y., Liu, Q., Qin, J., Wang, L., Ai-li, X., Qi, B., Sun, C., Xie, Y., Ma, Y., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.019 · Cited by 28
Lucateli, R. L., Silva, P. H. F., Salvador, S. L. D. S., Ervolino, E., Furlaneto, F. A. C., Marciano, M. A., Antunes, T. B. M., Arco, M. C. G. D., Tardelli, M. D. C., de Sousa, L. G., et al. (2024) · Journal of Periodontal Research · doi:10.1111/jre.13256 · Cited by 29
Chen, Y., Xiao, H., Liu, Z., Teng, F., Yang, A., Geng, B., Sheng, X., & Xia, Y. (2024) · Biomolecules · doi:10.3390/biom14080970 · Cited by 35
“Bone conversion is a tightly regulated process involving the coordinated activity of osteoclasts and osteoblasts to ensure continuous bone repair and the maintenance of bone strength [42].”
BackgroundBeavers, K. M., Lynch, S. D., Fanning, J. T., Howard, M. J., Lawrence, E., Lenchik, L., Shapses, S. A., Weaver, A. A., Wherry, S. J., Zamora, Z., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.16772 · Cited by 29
Variabilidad en las recomendaciones para el abordaje clínico de la osteoporosis
Sanfélix‐Genovés, J., Catalá-López, F., Sanfélix‐Gimeno, G., et al. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2012.10.025 · Cited by 24
Physicians' Attitudes to Contemporary Issues on Osteoporosis Management in Korea
Ha, Y., Lee, Y., Lim, Y.-T., Jang, S.-M., & Shin, C. S. (2014) · Journal of Bone Metabolism · doi:10.11005/jbm.2014.21.2.143 · Cited by 24
on behalf of the PAADRN Investigators, Cram, P. M., Wolinsky, F. D., Lou, Y., Edmonds, S. W., Hall, S. F., Roblin, D. W., Wright, N. C., Jones, M., & Saag, K. G. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3681-9 · Cited by 25
Association between primary biliary cholangitis and osteoporosis: meta-analysis
Fan, J., Wang, Q., & Sun, L. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3844-x · Cited by 26
Prevalence and associated risk factors for osteoporosis in Korean men
Yoo, J. E., & Park, H. S. (2018) · Archives of Osteoporosis · doi:10.1007/s11657-018-0506-9 · Cited by 26
Leslie, W. D., Luo, Y., Yang, S., Goertzen, A. L., Ahmed, S. I., Delubac, I., & Lix, L. M. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.02.001 · Cited by 26
Preoperative bisphosphonate treatment may adversely affect the outcome after shoulder arthroplasty
Mai, D. H., Oh, C., Doany, M. E., Rokito, A. S., Kwon, Y. W., Zuckerman, J. D., & Virk, M. S. (2019) · The Bone & Joint Journal · doi:10.1302/0301-620x.101b2.bjj-2018-0906.r1 · Cited by 24
Doolittle, M. L., Calabrese, G. M., Mesner, L. D., Godfrey, D. A., Maynard, R. D., Ackert‐Bicknell, C. L., & Farber, C. R. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008805 · Cited by 29
“Furthermore, several environmental factors such as smoking [22], air pollution [23], alcohol consumption [24], high fat diets [25] and use of common medications such as proton pump inhibitors [26], barbiturates [27], glucocorticoids [28], and nonsteroidal anti-inflammatory drugs (NSAIDS) [29] are associated with reduc…”
BackgroundWong, C. P., Gani, L. U., & Chong, L. R. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00808-2 · Cited by 24
Talevski, J., Sanders, K. M., Busija, L., Beauchamp, A., Duque, G., Borgström, F., Kanis, J. А., Svedbom, A., Connaughton, C., Stuart, A. L., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4181 · Cited by 24
“An estimated 200 million people aged 50 years or older are currently diagnosed with osteoporosis,((1,2)) making it the most common skeletal condition worldwide.((3)) A fragility fracture of the hip, distal forearm, vertebrae, or humerus— collectively referred to as major osteoporotic fracture (MOF)— is the most preval…”
BackgroundPrevalence and Treatment of Osteoporosis Prior to Elective Shoulder Arthroplasty
Bernatz, J. T., Brooks, A. E., Nguyen, B. P., et al. (2020) · JAAOS Global Research and Reviews · doi:10.5435/jaaosglobal-d-20-00204 · Cited by 24
Nutrition in Physical Therapist Practice: Setting the Stage for Taking Action
Berner, P., Bezner, J. R., Morris, D. M., & Lein, D. H. (2021) · Physical Therapy · doi:10.1093/ptj/pzab062 · Cited by 26
MRI-based Texture Analysis of Trabecular Bone for Opportunistic Screening of Skeletal Fragility
Zaworski, C., Cheah, J. T. L., Koff, M. F., Breighner, R. E., Lin, B. Q., Harrison, J., Donnelly, E. L., & Stein, E. M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab342 · Cited by 26
Singer, A. J., Liu, J.-M., Yan, H., Stad, R. K., Gandra, S. R., & Yehoshua, A. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05951-1 · Cited by 24
Waltman, N. L., Kupzyk, K. A., Flores, L. E., Mack, L. R., Lappe, J. M., & Bilek, L. D. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06083-2 · Cited by 27
Pang, X., Zhong, Z. A., Jiang, F., Yang, J., & Nie, H. (2022) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-022-02949-1 · Cited by 25
“Patients with spinal or hip fractures caused by OP may experience serious complications such as pulmonary infection and thrombotic diseases due to prolonged bed rest, which ultimately may result in fatal outcome [4, 5].”
BackgroundSclerostin as a biomarker of physical exercise in osteoporosis: A narrative review
Oniszczuk, A., Kaczmarek, A., Kaczmarek, M., Ciałowicz, M., Arslan, E., Silva, A. F., Clemente, F. M., & Murawska‐Ciałowicz, E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.954895 · Cited by 32
“5 million (7), 800,000 more have already been recorded in 2019 (6, 7).”
BackgroundResultHuang, Z., Wang, X., Wang, H., Zhang, S., Du, X., & Wei, H. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1045020 · Cited by 25
“Guidelines have recommended BMD screening for osteoporosis in women aged 65 years or older but clinical risk assessment tools for screening osteoporosis in younger women (21, 22).”
Polish guidelines for the diagnosis and management of osteoporosis: a review of 2013 update
Głuszko, P., Lorenc, R. S., Karczmarewicz, E., Misiorowski, W., & Jaworski, M. (2014) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.2255 · Cited by 28
How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women
Zhang, Z., Ou, Y., Sheng, Z., & Liao, E. (2013) · Endocrine · doi:10.1007/s12020-013-0076-y · Cited by 26
COPD and Associated Comorbidities: A Review of Current Diagnosis and Treatment
Carlin, B. W. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2582 · Cited by 24
He, J., Yang, L., Qing, Y., & He, C. (2013) · Acupuncture in Medicine · doi:10.1136/acupmed-2012-010271 · Cited by 24
Rest-activity patterns and falls and fractures in older men
Rogers, T., Blackwell, T., Lane, N. E., Tranah, G. J., ORWOLL, E. S., Cauley, J. A., Ancoli‐Israel, S., Stone, K. L., Cummings, S. R., & Cawthon, P. M. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3874-2 · Cited by 28
Vranken, L., Wyers, C. E., van der Velde, R. Y., Janzing, H. M. J., Kaarsemaker, S., Geusens, P., & van den Bergh, J. P. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4290-y · Cited by 27
Warm Needle Acupuncture in Primary Osteoporosis Management: A Systematic Review and Meta-Analysis
Luo, D., Liu, Y., Wu, Y., Ma, R., Wang, L., Gu, R., & Fu, W. (2018) · Acupuncture in Medicine · doi:10.1136/acupmed-2016-011227 · Cited by 25
Reduced bone mineral density among HIV-infected, virologically controlled young men
Shaiykova, A., Pasquet, A., Goujard, C., Lion, G., Durand, E., Bayan, T., Lachâtre, M., Choisy, P., Ajana, F., Bourdic, K., et al. (2018) · AIDS · doi:10.1097/qad.0000000000002001 · Cited by 24
FRAX® based intervention thresholds for management of osteoporosis in Singaporean women
Chandran, M., McCloskey, E. V., Thu, W. P. P., Logan, S. J. S., Hao, Y., Tay, D., Ang, W. C., Aung, T., Choo, K. S., Ali, A., et al. (2018) · Archives of Osteoporosis · doi:10.1007/s11657-018-0542-5 · Cited by 26
Sale, J. E. M., Marwah, A., Naeem, F., Yu, W. Y., & Meadows, L. M. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04913-y · Cited by 23
Zhao, B., Xing, G., & Wang, Y. (2019) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-019-1512-3 · Cited by 27
Trends in Dual-Energy X-Ray Absorptiometry in the United States, 2000–2009
O’Malley, C. D., Johnston, S. S., Lenhart, G. M., Cherkowski, G., Palmer, L. A., & Morgan, S. L. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.03.003 · Cited by 24
Kang, S., Kim, H. J., & Kim, M. (2012) · Biological Trace Element Research · doi:10.1007/s12011-012-9527-1 · Cited by 24
Fracture History in Osteoporosis: Risk Factors and its Effect on Quality of Life
Bektaşoğlu, P. K., Akyüz, G., Cerşit, H. P., et al. (2014) · Balkan Medical Journal · doi:10.5152/balkanmedj.2014.13265 · Cited by 24
de Abajo, F. J., Rodríguez‐Martín, S., Rodríguez, A., & Gil, M. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005795 · Cited by 31
Electrospinning-based bone tissue scaffold construction: Progress and trends
Ma, Y., Zhou, R., Yang, M., Zhang, J., Song, W. F., Ma, X., Liu, M., Cui, X., Li, B., Zhang, Y., et al. (2025) · Materials & Design · doi:10.1016/j.matdes.2025.113792 · Cited by 37
Ölmez, N., Yavaşi, S. K., Tan, G., Satiroglu, S., Yildiz, A. H., Öz, B., Yoleri, Ö., & Memiş, A. (2014) · Clinical Rheumatology · doi:10.1007/s10067-014-2491-8 · Cited by 23
Secondary prevention and estimation of fracture risk
Mitchell, P., & Chem, C. (2013) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2013.11.004 · Cited by 24
Klop, C., Welsing, P. M. J., Leufkens, H. G. M., Elders, P. J. M., Overbeek, J. A., van den Bergh, J. P., Bijlsma, J. W. J., & de Vries, F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143800 · Cited by 28
Cheng, T., Lai, H., Yu, S., Chiu, W.-C., Hsu, C., Chen, J., & Chen, Y. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000723 · Cited by 24
Association between polycyclic aromatic hydrocarbons and osteoporosis: data from NHANES, 2005–2014
Duan, W., Xin, M., Sun, Y., & Jia, C. (2018) · Archives of Osteoporosis · doi:10.1007/s11657-018-0527-4 · Cited by 23
Jeon, H., Oh, I., Baek, Y., Yang, H., Park, J., Hong, S., & Shin, J. (2019) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-01052-6 · Cited by 31
Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients
Xie, J., Li, S., Xiao, L., Ouyang, G., Zheng, L., Gu, Y., Gao, C., & Han, X.-W. (2019) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-019-1492-3 · Cited by 25
Başgöz, B. B., İnce, S., Safer, U., Naharcı, M. İ., & Taşçı, İ. (2020) · Turkish Journal of Physical Medicine and Rehabilitation · doi:10.5606/tftrd.2020.3803 · Cited by 25
“A routine patient care also covered ordering a repeated BMD measurement, where indicated.[19] Individuals with no difficulty in activities of daily living, but with memory impairment and lower scores on the Mini-Mental State Examination (MMSE) (scores between 19 and 23 out of 30) were classified as having MCI.”
BackgroundResultDevikanniga, D. (2020) · International Journal of Intelligent Networks · doi:10.1016/j.ijin.2020.05.004 · Cited by 25
Guo, F., Song, X., Li, Y., Guan, W., Pan, W. R., Yu, W., Li, T., & Hsieh, E. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05584-w · Cited by 27
Palanca, M., Perilli, E., & Martelli, S. (2020) · Annals of Biomedical Engineering · doi:10.1007/s10439-020-02682-y · Cited by 23
Skrzypczak, D., Ratajczak, A. E., Szymczak‐Tomczak, A., Dobrowolska, A., Eder, P., & Krela‐Kaźmierczak, I. (2021) · Nutrients · doi:10.3390/nu13020293 · Cited by 29
Zeytinoglu, M., Wroblewski, K., Vokes, T., Huisingh-Scheetz, M. J., Hawkley, L. C., & Huang, E. S. (2021) · Gerontology and Geriatric Medicine · doi:10.1177/2333721421989217 · Cited by 33
“Falls are associated with increased morbidity, mortality, reduced functioning, and high rates of admission to long-term care facilities (Cosman et al., 2014; Panel on Prevention of Falls in Older Persons, American Geriatrics Society and British Geriatrics Society, 2011; Tinetti, 2003).”
BackgroundKılınç, R. M., Açan, A. E., Türk, G., et al. (2021) · Acta Radiologica · doi:10.1177/02841851211021035 · Cited by 23
Bone Imaging and Fracture Risk after Spinal Cord Injury
Edwards, W. B., & Schnitzer, T. J. (2015) · Current Osteoporosis Reports · doi:10.1007/s11914-015-0288-6 · Cited by 25
Li, G., Thabane, L., Παπαϊωάννου, Α., & Adachi, J. D. (2015) · Bone · doi:10.1016/j.bone.2015.04.028 · Cited by 30
Korpi-Steiner, N. L., Milhorn, D. M., & Hammett‐Stabler, C. A. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.03.026 · Cited by 26
Vitamin D status of older adults of diverse ancestry living in the greater Toronto area
Ginter, J. K., Krithika, S., Gozdzik, A., Hanwell, H., Whiting, S. J., & Parra, E. J. (2013) · BMC Geriatrics · doi:10.1186/1471-2318-13-66 · Cited by 27
Farr, J. N., Khosla, S., Achenbach, S. J., Atkinson, E. J., Kirmani, S., McCready, L. K., Melton, L. J., & Amin, S. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2257 · Cited by 25
How to predict the risk of fracture in HIV?
Yin, M. T., & Falutz, J. (2016) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000273 · Cited by 26
Beyond Dxa: Advances in Clinical Applications of New Bone Imaging Technology
Pawłowska, M., & Bilezikian, J. P. (2016) · Endocrine Practice · doi:10.4158/ep151019.ra · Cited by 25
Do 25-Hydroxyvitamin D Levels Correlate With Fracture Complications?
Bodendorfer, B. M., Cook, J. L., Robertson, D. S., Rocca, G. J. D., Volgas, D. A., Stannard, J. P., & Crist, B. D. (2016) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000000639 · Cited by 23
Management of Osteoporotic and Neuropathic Ankle Fractures in the Elderly
Hoogervorst, P., van Bergen, C. J. A., & van den Bekerom, M. (2017) · Current Geriatrics Reports · doi:10.1007/s13670-017-0196-y · Cited by 25
Lewiecki, E. M. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0350-7 · Cited by 25
Self-citationAfter the fall: improving osteoporosis treatment following hip fracture
Kuiper, B. W., Graybill, S. D., Tate, J. M., Kaufman, N., & Bersabe, D. K. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4416-x · Cited by 27
Impact of Pharmacist-Physician Collaboration on Osteoporosis Treatment Rates
Bowers, B. L., Drew, A. M., & Verry, C. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018770622 · Cited by 23
Salamanna, F., Borsari, V., Contartese, D., Aldini, N. N., & Fini, M. (2018) · The Breast · doi:10.1016/j.breast.2018.06.013 · Cited by 24
Chisati, E. M., Constantinou, D., & Lampiao, F. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01074 · Cited by 23
Treatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies
Chang, B., Quan, Q., Li, Y., Qiu, H., Jiang, P., & Gu, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.912309 · Cited by 25
Dimai, H. P., Ljuhar, R., Ljuhar, D., et al. (2018) · Skeletal Radiology · doi:10.1007/s00256-018-3118-y · Cited by 23
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.